Eris Lifesciences Share Price Target 2027: Base and Bull Targets Built on FY26 Earnings

Investors weighing an Eris Lifesciences target price for 2027 should start with where the stock sits today. At Rs 1,165.60 on 9 October 2026, it is 33.0% below its 52-week high of Rs 1,740.00 and 2.2% above its 52-week low of Rs 1,141.00. That range spans 52% from low to high, so the entry point matters as much as the Eris Lifesciences price forecast itself.

This article builds the Eris Lifesciences share price target from reported numbers only: five years of annual results, the last five quarters, the latest shareholding pattern and current valuation ratios from company filings and exchange data. Each scenario shows its assumptions, so you can see exactly how the Rs 1,379 base case and the Rs 1,652 bull case were reached, along with a downside risk level of Rs 919.

Click Here – Get Free Investment Predictions

Eris Lifesciences Stock Analysis: Company Overview and Key Stats

Eris Lifesciences (NSE: ERIS) has a market capitalisation of Rs 15,943 crore. In FY26 it reported revenue of Rs 3,137 crore and net profit of Rs 647.51 crore. The table collects the figures the Eris Lifesciences share price target is built on.

Metric	Value
Company	Eris Lifesciences
NSE Ticker	ERIS
CMP (9 October 2026)	Rs 1,165.60
52-Week High	Rs 1,740.00
52-Week Low	Rs 1,141.00
Market Cap	Rs 15,943 crore
PE Ratio (TTM)	23.95
Industry PE	37.59
Price to Book	4.09
Return on Equity	15.87%
Debt to Equity	0.60
EPS (TTM)	Rs 47.98
Dividend Yield	0.63%
12-Month Base Target	Rs 1,379
Bull Case	Rs 1,652
Downside Risk Level (not a target)	Rs 919

Why Is Eris Lifesciences Share Price Target Set at Rs 1,379 for 2027?

The base-case Eris Lifesciences stock target of Rs 1,379 applies a PE multiple of 23.95 to a forward EPS estimate of Rs 57.58. That EPS assumes 20.0% yearly growth, the pace from FY24 to FY26, and puts the target 18.3% above the current price. The bull case adds faster earnings growth and a higher multiple, while the downside risk level assumes flat earnings and a lower multiple.

Earnings Growth Behind the Eris Lifesciences Target Price: Five Years of Results

Eris Lifesciences grew revenue from Rs 1,373 crore in FY22 to Rs 3,137 crore in FY26, a compound annual growth rate of 22.9%. Net profit grew more slowly, from Rs 405.79 crore to Rs 647.51 crore (12.4% a year), which points to margin pressure alongside the sales growth.

Financial Year	Revenue (Rs Cr)	Net Profit (Rs Cr)	EPS (Rs)	Dividend per Share (Rs)
FY22	1,373.14	405.79	29.88	6.01
FY23	1,696.30	374.16	28.07	7.35
FY24	2,032.97	397.12	28.79	0.00
FY25	2,912.00	374.67	25.81	7.35
FY26	3,137.17	647.51	45.26	7.21

FY26 revenue growth was 7.7%, slower than the four-year average of 22.9%, and net profit moved up 72.8%. EPS rose from Rs 28.79 in FY24 to Rs 45.26 in FY26. The FY27 outlook depends on whether that EPS estimate keeps compounding.

Margins and the Latest Quarter

Eris Lifesciences converted 20.6% of FY26 revenue into net profit, against 12.9% in FY25, within a five-year range of 12.9% to 29.6%. EBITDA margin was 35.4% in FY26 versus 35.6% in FY25.

In the June 2026 quarter, revenue was Rs 875.64 crore, up 12.9% from the same quarter a year earlier, while net profit of Rs 143.32 crore was up 14.6%. EBITDA came in at Rs 298.61 crore, up 6.9% year on year. The next quarterly result is the first test of whether the earnings assumption holds.

Balance Sheet and Cash Flow

Debt to equity stands at 0.60, and shareholders' equity grew from Rs 1,908 crore in FY22 to Rs 3,896 crore in FY26. Operating cash flow in FY26 was Rs 537.99 crore against capital expenditure of Rs 296.86 crore, leaving free cash flow of Rs 241.13 crore, or 1.5% of the current market capitalisation. In FY25 free cash flow was Rs 910.01 crore.

Valuation Check for the Eris Lifesciences Stock Target: PE, Price to Book and ROE

At a PE of 23.95 against an industry PE of 37.59, Eris Lifesciences trades at a discount to its industry. Price to book is 4.09 on a book value of Rs 281.30 per share, and return on equity is 15.87%. A PE of 23.95 equals an earnings yield of 4.2%, and the FY26 dividend of Rs 7.21 per share gives a yield of 0.63%.

Shareholding Pattern and Institutional Holding

Promoters held 54.14% of Eris Lifesciences in June 2026, and promoter holding fell from 54.84% in June 2025 to 54.14% in June 2026. Foreign institutional investors (FII) held 5.75% and domestic institutions (DII) held 20.72%, which puts total institutional holding at 26.47%. FII holding fell from 8.40% in June 2025 to 5.75% in June 2026. Public shareholders own the remaining 19.40%. A meaningful institutional holding adds a layer of research coverage and trading depth.

Eris Lifesciences Share Price Targets for the Short Term and 12 Months

Short Term Eris Lifesciences Stock Target Levels: Technical Setup

At Rs 1,165.60 on 9 October 2026, Eris Lifesciences trades below its 50-day simple moving average of Rs 1,305.51 and below its 200-day exponential moving average of Rs 1,385.90. The 14-day RSI reads 12.3, which is oversold territory, and the MACD line sits below its signal line. The nearest resistance level is Rs 1,305.51 (50-day simple moving average) and the nearest support is Rs 1,141.00 (52-week low). A sustained move above Rs 1,305.51 would improve the short-term setup, while a close below Rs 1,141.00 would shift attention to the next support.

12 Month Eris Lifesciences Target Price for 2027

The 12-month target for Eris Lifesciences is Rs 1,379: forward EPS of Rs 57.58 at a PE of 23.95. That is 18.3% above Rs 1,165.60. It would still leave the stock 20.7% below its 52-week high of Rs 1,740.00.

How EPS Growth and PE Multiple Change the Eris Lifesciences Target Price

EPS Growth	PE 19.16	PE 23.95	PE 27.54
0.0% (EPS Rs 47.98)	Rs 919	Rs 1,149	Rs 1,321
20.0% (EPS Rs 57.58)	Rs 1,103	Rs 1,379	Rs 1,586
25.0% (EPS Rs 59.97)	Rs 1,149	Rs 1,436	Rs 1,652

Each cell multiplies the forward EPS estimate by the PE shown. Reading across a row shows what a de-rating or re-rating does to the Eris Lifesciences price forecast, and reading down a column shows what earnings growth is worth at a fixed multiple.

Bull Case and Downside Risk for Eris Lifesciences Stock Target in 2027

Bull Case Rs 1,652

The bull case Eris Lifesciences price target needs EPS growth of 25.0%, which lifts forward EPS to Rs 59.97, and a PE multiple that rises 15% to 27.54. That gives Rs 1,652, 41.7% above the current price and below the 52-week high of Rs 1,740.00.

Downside Risk Level Rs 919

The downside risk level is not a target. It assumes EPS stays flat at Rs 47.98 and the PE falls 20% to 19.16. That gives Rs 919, 21.2% below the current price and below the 52-week low of Rs 1,141.00.

Scenario	EPS Growth	PE Multiple	Price (Rs)	Change vs CMP
Bull Case	25.0%	27.54	Rs 1,652	+41.7%
Base Case	20.0%	23.95	Rs 1,379	+18.3%
Downside Risk	0.0%	19.16	Rs 919	-21.2%

Key Risks to the Eris Lifesciences Target Price for 2027

Growth Slowdown Risk for the Eris Lifesciences Price Target

Revenue in the June 2026 quarter was up 12.9% year on year, and FY26 revenue growth was 7.7%. If growth slows from here, the EPS estimate behind the Eris Lifesciences stock target will need revising.

Liquidity and Size Risk

Eris Lifesciences has a market capitalisation of Rs 15,943 crore. Institutional holding is 26.47%, and promoters hold 54.14%. Stocks of this size are usually liquid, though exits can take longer than entries when the market is falling.

Valuation and Margin Risk

Net margin was 20.6% in FY26, and a squeeze from higher costs or weaker pricing would hit earnings first. At a PE of 23.95 versus an industry PE of 37.59, a de-rating toward the downside-risk PE of 19.16 would cut the price even if earnings hold.

Market and Technical Risk

The stock trades 33.0% below its 52-week high, with an RSI of 12.3 and a MACD reading below its signal line. Broader market weakness can override company fundamentals in the short term.

How to Invest in Eris Lifesciences

Start with the live price and volume. Any Eris Lifesciences share price target is only as current as the data behind it, and the data here is as of 9 October 2026, so refresh the Rs 1,165.60 price before acting on any level.

Next, review the fundamentals yourself. The Univest Screener lets you check Eris Lifesciences' PE, ROE, debt and shareholding in one place.

Check Eris Lifesciences fundamentals on the Univest Screener

Then compare the three Eris Lifesciences target price scenarios with your own view. If you expect EPS growth below 20.0%, the base case is too optimistic for you; if you expect more, the bull case deserves weight.

Decide your position size and exit levels before you buy. The support and resistance levels above can serve as reference points, but they are not recommendations.

Finally, place the order through a SEBI-registered broker or the Univest app, and review the position after each quarterly result. Consult a SEBI-registered advisor if you are unsure.

Download the Univest iOS App or Univest Android App to track Eris Lifesciences live price and get daily stock recommendations.

Conclusion

The Eris Lifesciences share price target for 2027 is Rs 1,379 in the base case, with Rs 1,652 as the bull case. The support for that view is arithmetic you can check: EPS grew 25.4% a year over FY24 to FY26, and the stock trades at a PE of 23.95. The risks are equally concrete, including a stock that sits 33.0% below its 52-week high and a downside scenario that cuts the price 21% if earnings stall. Use these numbers as a framework, check them against the latest filings, and size any position to your own risk appetite.

FAQs on Eris Lifesciences Share Price Target 2027

What is the Eris Lifesciences share price target for 2027?

Ans. The base-case Eris Lifesciences share price target for 2027 is Rs 1,379, with Rs 1,652 as the bull case. The downside risk level, which is not a target, is Rs 919. These are model estimates from reported earnings and the current PE, not guaranteed outcomes.

What is the Eris Lifesciences share price today?

Ans. As of 9 October 2026, 1:18 PM IST, Eris Lifesciences trades at Rs 1,165.60, up 0.91% on the day. The 52-week range is Rs 1,141.00 to Rs 1,740.00.

Is Eris Lifesciences a buy or sell at the current price?

Ans. The data is mixed rather than one-sided: EPS has grown 25.4% a year over FY24 to FY26, but the stock is 33.0% below its 52-week high. Whether Eris Lifesciences fits your portfolio depends on your time horizon and risk appetite, so consult a SEBI-registered advisor before investing. This article is not investment advice.

What are the bull case target and downside risk level for Eris Lifesciences shares?

Ans. The bull case target is Rs 1,652, which assumes 25.0% EPS growth and a PE of 27.54. The downside risk level is Rs 919, which assumes flat EPS and a PE of 19.16. It marks a risk, not a target.

What are the main risks to the Eris Lifesciences price target?

Ans. The main risks are slower revenue growth, a small market capitalisation of Rs 15,943 crore, a PE de-rating and short-term weakness in the broader market. Each is covered in the risk section above.

What is the PE ratio of Eris Lifesciences and how does it compare with the industry?

Ans. The PE ratio of Eris Lifesciences is 23.95 against an industry PE of 37.59. Price to book is 4.09 and return on equity is 15.87%. The base case in the Eris Lifesciences price target holds this PE constant.

Who owns Eris Lifesciences, and what is the promoter holding?

Ans. Promoters held 54.14% of Eris Lifesciences in June 2026. FII held 5.75%, DII held 20.72% and the public held 19.40%.

What were Eris Lifesciences' latest quarterly results?

Ans. In the June 2026 quarter, Eris Lifesciences reported revenue of Rs 875.64 crore (up 12.9% year on year) and net profit of Rs 143.32 crore (up 14.6%).